Aspen Neuroscience (NASDAQ:ASPE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Aspen Neuroscience (NASDAQ:ASPE – Free Report) to a hold rating in a report released on Saturday morning,Wall Street Zen reports.

Aspen Neuroscience Stock Down 1.4%

NASDAQ ASPE opened at $12.42 on Friday. Aspen Neuroscience has a 12-month low of $11.20 and a 12-month high of $14.90.

Insider Transactions at Aspen Neuroscience

In other Aspen Neuroscience news, major shareholder Venture Fund X. L.P. Arch purchased 1,200,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The stock was bought at an average cost of $15.00 per share, for a total transaction of $18,000,000.00. Following the completion of the transaction, the insider owned 1,200,000 shares in the company, valued at approximately $18,000,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Orbimed Advisors Llc purchased 1,000,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The stock was acquired at an average price of $15.00 per share, with a total value of $15,000,000.00. Following the completion of the transaction, the director owned 3,589,132 shares of the company’s stock, valued at $53,836,980. This represents a 38.62% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have acquired 3,333,333 shares of company stock valued at $49,999,995.

About Aspen Neuroscience

(Get Free Report)

Aspen Neuroscience, Inc. is a biotechnology company focused on developing regenerative medicine therapies for neurological disorders. The company’s approach uses a patient’s own cells to create induced pluripotent stem cells, which are then differentiated into specialized cells intended to replace damaged or lost tissue. Aspen’s lead program, ANPD001, is designed as a potential cell replacement therapy for Parkinson’s disease. The company has also developed genetic screening and manufacturing processes intended to evaluate a patient’s cells and produce an individualized therapeutic product.

Further Reading

Receive News & Ratings for Aspen Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.